Press Release

09. April 2018
WAYLAND, MASSACHUSETTS, April 9, 2018 -- Earlier today, Syneron Medical Ltd and its subsidiary Candela Corporation (collectively, Syneron Candela) and Massachusetts General Hospital (MGH) filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. International Trade Commission in Washington, D.C. and in federal district court. The accused infringing products include Secret RF by ilooda Co., Ltd. and Cutera, Inc.; Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics... Read More
17. Juli 2017
Announces new executive leadership team headquartered in the U.S. Syneron Medical Ltd. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, today announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transaction was announced on April 3, 2017 and received approval from Syneron Candela's shareholders on June 15, 2017. As a result of the transaction, Syneron Candela is now a privately held company. Syneron Candela's ordinary shares... Read More
15. Juni 2017
Syneron Medical Ltd. (NASDAQ: ELOS) today announced that its shareholders have approved the previously announced definitive agreement under which an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million (the "Merger Agreement").  93.3% of the ordinary shares voting at the special shareholder meeting were voted in favor of the Merger Agreement. The acquisition is expected to be completed in mid-July, subject to the satisfaction of the remaining... Read More
17. Mai 2017
Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended March 31, 2017.   First Quarter 2017 Financial Highlights: Revenue of $66.9 million, down 2.6% year-over-year Product revenue down 4.2% year-over-year International product revenue grew 7.7% year-over-year while North America product revenue declined 31.7% year-over-year as a result of the sales force reorganization Revenue from emerging products1, which represent the Company's strategic growth drivers, grew 3.5% year-over-... Read More
KONTAKT
PATIENTEN